GSK receives EC approval for the sale of ThermaCare

Issued: London, UK

GSK announces that the European Commission has formally approved a deal for the sale of the rights for its ThermaCare business globally, excluding North America, to Angelini Pharma.  The deal also includes the dedicated US manufacturing site for ThermaCare in Albany, Georgia.  The approval follows legally binding commitments made by GSK in July 2019 to divest the ThermaCare business as a condition of the EC’s antitrust clearance for the joint venture between GSK Consumer Healthcare and Pfizer Consumer Healthcare.